Medicover Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Fredrik Rågmark

Chief Executive Officer (CEO)

€2.6m

Compensación total

Porcentaje del salario del CEO	39.0%
Permanencia del CEO	27.3yrs
Participación del CEO	1.0%
Permanencia media de la dirección	3.7yrs
Promedio de permanencia en la Junta Directiva	14.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Fredrik Rågmark en comparación con los beneficios de Medicover?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	€18m
Sep 30 2023	n/a	n/a	€8m
Jun 30 2023	n/a	n/a	€6m
Mar 31 2023	n/a	n/a	€2m
Dec 31 2022	€3m	€1m	€12m
Sep 30 2022	n/a	n/a	€37m
Jun 30 2022	n/a	n/a	€59m
Mar 31 2022	n/a	n/a	€88m
Dec 31 2021	€2m	€952k	€102m
Sep 30 2021	n/a	n/a	€93m
Jun 30 2021	n/a	n/a	€90m
Mar 31 2021	n/a	n/a	€52m
Dec 31 2020	€2m	€670k	€26m
Sep 30 2020	n/a	n/a	€14m
Jun 30 2020	n/a	n/a	€4m
Mar 31 2020	n/a	n/a	€16m
Dec 31 2019	€1m	€900k	€23m
Sep 30 2019	n/a	n/a	€19m
Jun 30 2019	n/a	n/a	€19m
Mar 31 2019	n/a	n/a	€20m
Dec 31 2018	€1m	€807k	€22m
Sep 30 2018	n/a	n/a	€28m
Jun 30 2018	n/a	n/a	€26m
Mar 31 2018	n/a	n/a	€23m
Dec 31 2017	€921k	€810k	€19m

Compensación vs. Mercado: Fredrik($USD2.82M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD2.10M).

Compensación vs. Ingresos: Fredrikha sido coherente con los resultados de la empresa en el último año.

CEO

Fredrik Rågmark (60 yo)

27.3yrs

Permanencia

€2,602,000

Compensación

Mr. Fredrik Ragmark serves as the Chief Executive Officer of Medicover AB (publ). Mr. Ragmark has been employed with Medicover since 1996. He serves as Managing Director and Board Member of Kalvskär AB.Fr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Fredrik Rågmark	CEO & Director	no data	€2.60m	1.05% € 212.4m
Joe Ryan	Chief Financial Officer	no data	sin datos	0.99% € 200.5m
Jaroslaw Urbanczyk	Chief Information Officer	4.5yrs	sin datos	0.0040% € 821.0k
Hanna Bjellquist	Head of Investor Relations	no data	sin datos	sin datos
Jenny Brandt	General Legal Counsel	no data	sin datos	0.035% € 7.1m
Andrew Vallance-Owen	Chief Marketing Officer	no data	sin datos	sin datos
Kamila Skorupinski	Group Chief People Officer	no data	sin datos	sin datos
John Stubbington	Chief Operating Officer of Healthcare Services	8.2yrs	sin datos	0.49% € 98.7m
Staffan Ternstrom	Chief Operating Officer for Diagnostic Services	2.8yrs	sin datos	0.033% € 6.8m

3.7yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: 0RPSEl equipo directivo de la empresa se considera experimentado (3.7 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Fredrik Rågmark	CEO & Director	27.3yrs	€2.60m	1.05% € 212.4m
Robert Jochnick	Independent Director	17.3yrs	€54.60k	1.22% € 247.1m
Fredrik Stenmo	Independent Chairman	19.3yrs	€101.50k	4.42% € 897.5m
Margareta Nordenvall	Independent Director	23.3yrs	€66.20k	0.11% € 22.9m
Arno Bohn	Independent Director	23.3yrs	€63.05k	0.20% € 40.7m
Cecil Michael Flemming	Independent Director	9.3yrs	€78.30k	sin datos
Anne Berner	Independent Director	2yrs	€59.85k	sin datos
Azita Shariati	Independent Director	2yrs	€63.05k	0.0015% € 298.7k
Peder Jochnick	Independent Director	12.3yrs	€54.60k	2.6% € 527.5m
Sonali Chandmal	Independent Director	7.3yrs	€71.45k	0.017% € 3.4m

14.8yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: 0RPSLos consejos de administración de la empresa son veteranos y experimentados ( 14.4 años de permanencia media en el cargo).

Medicover Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insider recently bought kr1.8m worth of stock

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Independent Chairman recently bought kr3.9m worth of stock

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Recent updates

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: €0.12 (vs €0.079 in FY 2022)

Dividend of €0.12 announced

Insider recently bought kr1.8m worth of stock

Full year 2023 earnings released: EPS: €0.12 (vs €0.081 in FY 2022)

Now 22% undervalued

Medicover AB (publ) Provides Earnings Guidance for the Financial Year 2025

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Independent Chairman recently bought kr3.9m worth of stock

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Third quarter 2023 earnings released

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Medicover AB (publ), Annual General Meeting, Apr 26, 2024

Independent Director recently bought kr1.4m worth of stock

Independent Chairman recently bought kr6.3m worth of stock

Second quarter 2023 earnings released: EPS: €0.037 (vs €0.01 in 2Q 2022)

Medicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024

Insider recently bought kr242k worth of stock

Chief Information Officer recently bought kr321k worth of stock

Upcoming dividend of €0.12 per share at 0.7% yield

Full year 2022 earnings released

Now 24% undervalued

Full year 2022 earnings released

Medicover AB (publ) Proposes Dividend for 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released

Medicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023

Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Medicover AB (publ) (OM:MCOV B) acquired Übag Mvz Meindentist Gbr.

Medicover AB (publ) (OM:MCOV B) completed the acquisition of Laurus Medical SRL.

Medicover AB (publ), Annual General Meeting, Apr 27, 2023

Second quarter 2022 earnings released

Independent Chairman recently bought kr2.8m worth of stock

Medicover AB (publ) (OM:MCOV B) acquired Konzilijum.

Investor sentiment deteriorated over the past week

Medicover AB (publ) (OM:MCOV B) signed an agreement to acquire Übag Mvz Meindentist Gbr.

High number of new directors

Medicover AB (publ) (OM:MCOV B) acquired Kliniki Terapii Allenort Holding Sp. z o.o.

Independent Chairman recently bought kr3.3m worth of stock

Medicover AB (Publ) Elects Anne Berner and Azita Shariati as Board Members

Full year 2021 earnings released: EPS: €0.69 (vs €0.18 in FY 2020)

Insufficient new directors

Upcoming dividend of €0.12 per share

Full year 2021 earnings released: EPS: €0.69 (vs €0.18 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

General Legal Counsel recently bought kr518k worth of stock

Now 24% undervalued after recent price drop

Medicover AB (publ) Proposes Dividend for the Financial Year 2021, Expected Payable on 6 May 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Medicover AB (publ) (OM:MCOV B) acquired an unknown majority stake in Mediplus Clinic.

Investor sentiment deteriorated over the past week

Chief Financial Officer recently sold kr1.4m worth of stock

Independent Director recently sold kr2.9m worth of stock

Third quarter 2021 earnings released

Medicover AB (publ) (OM:MCOV B) acquired 70% stake in Klinikk Hanne As for €18.2 million.

Medicover AB (publ) (OM:MCOV B) acquired 88.8% stake in Sellmerdiers Aps from Liza Diers and Anette Sellmer for €13.7 million.

Second quarter 2021 earnings released: EPS €0.20 (vs €0.056 loss in 2Q 2020)

Chief Information Officer recently bought kr109k worth of stock

Chief Information Officer recently bought kr161k worth of stock

Chief Information Officer recently bought kr161k worth of stock

First quarter 2021 earnings released

Full year 2020 earnings released: EPS €0.18 (vs €0.17 in FY 2019)

Full year 2020 earnings released: EPS €0.17 (vs €0.17 in FY 2019)

Revenue beats expectations